Effectiveness of image‐guided radiotherapy for locally advanced lung cancer patients treated with definitive concurrent chemoradiotherapy

Liang, Ji An; Tu, Chih‐Yen; Hsia, Te‐Chun; Fang, Hsin‐Yuan; Li, Chia‐Chin; Chien, Chun Ru

doi:10.1111/1759-7714.13596

Cited by 4 publications

(4 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To account for potential nonrandomized treatment selection, the following covariates were collected, based on recent relevant studies and our clinical research experiences: [5,[8][9][10]18] patient demographics (age, sex, residency region, and socioeconomic status (SES)), patient characteristics (body mass index (BMI), comorbidity, smoking, and performance status), and disease characteristics (clinical T-and N-stage, tumor size).…”

Section: Covariatesmentioning

confidence: 99%

Efficacy of Definitive Radiotherapy for Patients with Clinical Stage IIIB or IIIC Lung Adenocarcinoma and Epidermal Growth Factor Receptor (EGFR) Mutations Treated Using First- or Second-Generation EGFR Tyrosine Kinase Inhibitors

Tu,

Hsia,

Lin

et al. 2024

Canadian Respiratory Journal

Self Cite

View full text Add to dashboard Cite

Background. The effectiveness of definitive radiotherapy (RT) for patients with clinical stage IIIB or IIIC lung adenocarcinoma and epidermal growth factor receptor (EGFR) mutations who received first- or second-generation EGFR tyrosine kinase inhibitors (TKIs) is unclear. Methods. Taiwan Cancer Registry data were used in this retrospective cohort study to identify adult patients diagnosed with EGFR-mutated stage IIIB or IIIC lung adenocarcinoma between 2011 and 2020. Patients treated with first- or second-generation EGFR TKIs were classified into RT and non-RT groups. Propensity score (PS) weighting was applied to balance covariates between groups. The primary outcome was overall survival (OS), and the incidence of lung cancer mortality (ILCM) was considered as a supplementary outcome. Additional supplementary analyses were conducted to assess the robustness of the findings. Results. Among 270 eligible patients, 41 received RT and 229 did not. After a median follow-up of 46 months, PS-weighted analysis showed the PS-weighted hazard ratio of death for the RT group compared to the non-RT group was 0.94 (95% CI: 0.61–1.45, p=0.78). ILCM rates did not differ significantly between the two groups. Supplementary analyses yielded consistent results. Conclusion. The addition of definitive RT to first- or second-generation EGFR TKI treatment does not significantly improve OS of patients with EGFR-mutated stage IIIB or IIIC lung adenocarcinoma. NCT03521154NCT05167851.

show abstract

Section: Covariatesmentioning

confidence: 99%

Efficacy of Definitive Radiotherapy for Patients with Clinical Stage IIIB or IIIC Lung Adenocarcinoma and Epidermal Growth Factor Receptor (EGFR) Mutations Treated Using First- or Second-Generation EGFR Tyrosine Kinase Inhibitors

Tu,

Hsia,

Lin

et al. 2024

Canadian Respiratory Journal

Self Cite

View full text Add to dashboard Cite

show abstract

“…Published evidence on the role of image-guided radiation therapy (IGRT) in SCLC is limited. One study involving a series of 132 patients with SCLC[ 170 ] found no significant differences in OS between patients treated with or without IGRT. No toxicity information was reported.…”

Section: Rt Techniquesmentioning

confidence: 99%

GOECP/SEOR radiotherapy guidelines for small-cell lung cancer

Couñago

Pinta

Gonzalo

et al. 2021

WJCO

View full text Add to dashboard Cite

Small cell lung cancer (SCLC) accounts for approximately 20% of all lung cancers. The main treatment is chemotherapy (Ch). However, the addition of radiotherapy significantly improves overall survival (OS) in patients with non-metastatic SCLC and in those with metastatic SCLC who respond to Ch. Prophylactic cranial irradiation reduces the risk of brain metastases and improves OS in both metastatic and non-metastatic patients. The 5-year OS rate in patients with limited-stage disease (non-metastatic) is slightly higher than 30%, but less than 5% in patients with extensive-stage disease (metastatic). The present clinical guidelines were developed by Spanish radiation oncologists on behalf of the Oncologic Group for the Study of Lung Cancer/Spanish Society of Radiation Oncology to provide a current review of the diagnosis, planning, and treatment of SCLC. These guidelines emphasise treatment fields, radiation techniques, fractionation, concomitant treatment, and the optimal timing of Ch and radiotherapy. Finally, we discuss the main indications for reirradiation in local recurrence.

show abstract

“…The covariates were modified from the literature 12 as well as our experiences in clinical care 13 and TCR studies. 14,15…”

Section: Study Population and Study Designmentioning

confidence: 99%

Effectiveness of Image-Guided Radiotherapy in Adjuvant Radiotherapy on Survival for Localized Breast Cancer: A Population-Based Analysis

Liang

Lee

et al. 2021

CMAR

View full text Add to dashboard Cite

Image-guided radiotherapy (IGRT) is an advanced radiotherapy technique to improve the radiotherapy delivery. We aimed to compare the overall survival (OS) for localized breast cancer (LBC) patient treated with adjuvant conventional fractionated radiotherapy (CFRT) using IGRT vs those without IGRT via a population-based analysis. Patients and Methods: Eligible LBC patients diagnosed between 2011 and 2013 were identified via the Taiwan Cancer Registry. We used propensity score (PS) weighting to balance observable potential confounders between groups. The hazard ratio (HR) of death and other outcomes were compared between IGRT and non-IGRT. We also evaluated OS in various supplementary analyses. Results: Our primary analysis included 6490 patients in whom covariates were well balanced after PS weighing. The HR for death when IGRT was compared with non-IGRT was 1.02 (95% confidence interval 0.80-1.31, P = 0.86). There were also no significant differences in the supplementary analyses. Conclusion:We found that OS of LBC patients treated with adjuvant CFRT was not statistically different between those treated with IGRT versus without IGRT. This was the first study in this regard to our knowledge but randomized controlled trials were needed to confirm our finding.

show abstract

Effectiveness of image‐guided radiotherapy for locally advanced lung cancer patients treated with definitive concurrent chemoradiotherapy

Cited by 4 publications

References 27 publications

Efficacy of Definitive Radiotherapy for Patients with Clinical Stage IIIB or IIIC Lung Adenocarcinoma and Epidermal Growth Factor Receptor (EGFR) Mutations Treated Using First- or Second-Generation EGFR Tyrosine Kinase Inhibitors

Efficacy of Definitive Radiotherapy for Patients with Clinical Stage IIIB or IIIC Lung Adenocarcinoma and Epidermal Growth Factor Receptor (EGFR) Mutations Treated Using First- or Second-Generation EGFR Tyrosine Kinase Inhibitors

GOECP/SEOR radiotherapy guidelines for small-cell lung cancer

Effectiveness of Image-Guided Radiotherapy in Adjuvant Radiotherapy on Survival for Localized Breast Cancer: A Population-Based Analysis

Contact Info

Product

Resources

About